We are looking for a board-certified psychiatrist with strong clinical experience in mood disorders and a few years of exposure to clinical development or clinical studies. You will provide hands-on medical input to HMNC's programs in depression and treatment-resistant depression, including protocol development, medical monitoring, safety review and interpretation of emerging clinical data. Working closely with the Chief Medical Officer, VP Clinical Development and Clinical Development team, you will support protocol development, Sponsor oversight of medical monitoring/safety and the resolution of medical questions during clinical studies. The position combines specialist psychiatric judgment with practical study experience and complements HMNC's existing clinical development leadership.
HMNC Brain Health (HMNC) is a clinical-stage neuroscience company developing new therapies for mental health disorders. With an initial focus on difficult-to-treat depression, including treatment-resistant depression (TRD) and adjunctive therapies for major depressive disorder (MDD), HMNC's pipeline includes two late-stage programs. Lead asset Ketabon (KET01), partnered with MEDICE for European commercialization, is an oral prolonged-release ketamine formulation for TRD, designed for at-home use. Nelivabon (BH-200) is a first-in-class oral vasopressin receptor antagonist targeting the stress axis, with potential in adjunctive MDD/ TRD. By advancing targeted and accessible treatment options, HMNC aims to address significant unmet needs of millions of patients who are not helped sufficiently by existing mental health therapies. The Company is headquartered in Munich, Germany. Find out more at and connect with us on LinkedIn.
#J-18808-LjbffrVeröffentlichungsdatum:
23 Okt 2026Standort:
MünchenTyp:
VollzeitArbeitsmodell:
Vor OrtKategorie:
Erfahrung:
2+ yearsArbeitsverhältnis:
Angestellt
Möchtest über ähnliche Jobs informiert werden? Dann beauftrage jetzt den Fuchsjobs KI Suchagenten!